Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Miles

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2016
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationDavid Miles, David Cameron, Igor Bondarenko, et al.
Nucleic Acids Research|August 23, 2014
Essential role of eIF5-mimic protein in animal development is linked to control of ATF4 expressionHiroyuki Hiraishi, Jamie Oatman, Sherry L Haller, et al.
Cell Reports|July 21, 2012
The C-terminal domain of eukaryotic initiation factor 5 promotes start codon recognition by its dynamic interplay with eIF1 and eIF2βRafael E Luna, Haribabu Arthanari, Hiroyuki Hiraishi, et al.
Health Technology Assessment (Winchester, England)|September 4, 2020
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCTHelena Earl, Louise Hiller, Anne-Laure Vallier, et al.
CMAJ Open|October 24, 2019
Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV NetworkCarla S Coffin, Alnoor Ramji, Curtis L Cooper, et al.
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2016
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationDavid Miles, David Cameron, Igor Bondarenko, et al.
Nucleic Acids Research|August 23, 2014
Essential role of eIF5-mimic protein in animal development is linked to control of ATF4 expressionHiroyuki Hiraishi, Jamie Oatman, Sherry L Haller, et al.
Cell Reports|July 21, 2012
The C-terminal domain of eukaryotic initiation factor 5 promotes start codon recognition by its dynamic interplay with eIF1 and eIF2βRafael E Luna, Haribabu Arthanari, Hiroyuki Hiraishi, et al.
Health Technology Assessment (Winchester, England)|September 4, 2020
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCTHelena Earl, Louise Hiller, Anne-Laure Vallier, et al.
CMAJ Open|October 24, 2019
Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV NetworkCarla S Coffin, Alnoor Ramji, Curtis L Cooper, et al.
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
Pageof 6